visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Therapeutic potential of emerging NAD+-increasing strategies for cardiovascular diseases |
Data: | 2021 |
Resum: | Cardiovascular diseases are the leading cause of death worldwide. Aging and/or metabolic stress directly impact the cardiovascular system. Over the last few years, the contributions of altered nicotinamide adenine dinucleotide (NAD+) metabolism to aging and other pathological conditions closely related to cardiovascular diseases have been intensively investigated. NAD+ bioavailability decreases with age and cardiometabolic conditions in several mammalian tissues. Compelling data suggest that declining tissue NAD+ is commonly related to mitochondrial dysfunction and might be considered as a therapeutic target. Thus, NAD+ replenishment by either genetic or natural dietary NAD+-increasing strategies has been recently demonstrated to be effective for improving the pathophysiology of cardiac and vascular health in different experimental models, as well as human health, to a lesser extent. Here, we review and discuss recent experimental evidence illustrating that increasing NAD+ bioavailability, particularly by the use of natural NAD+ precursors, may offer hope for new therapeutic strategies to prevent and treat cardiovascular diseases. |
Ajuts: | Instituto de Salud Carlos III PI17/00232 Instituto de Salud Carlos III PI18/00164 Instituto de Salud Carlos III CPII18/00004 Agencia Estatal de Investigación RYC-201722879 |
Nota: | Altres ajuts: Fundació La Marató de TV3 (303/C/2016)(201602.30.31) |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | Macrophage ; Aneurysm ; Atherosclerosis ; Ischemia/reperfusion ; Cardiomyopathy ; Heart failure ; Chemotherapy ; Clinical trials ; COVID-19 ; Niacinamide ; Vitamin B3 ; Niacin ; Niagen ; Niaspan ; Mitochondria ; Tryptophan ; Diabetes ; Myocarditis ; Animal models |
Publicat a: | Antioxidants, Vol. 10 Núm. 12 (december 2021) , p. 1939, ISSN 2076-3921 |
41 p, 1.2 MB |